publication . Article . Other literature type . 2018

Immunosuppressive Mesenchymal Stromal Cells Derived from Human-Induced Pluripotent Stem Cells Induce Human Regulatory T Cells In Vitro and In Vivo.

Clémence Roux; Clémence Roux; Clémence Roux; Gaëlle Saviane; Gaëlle Saviane; Jonathan Pini; Jonathan Pini; Nourhène Belaïd; Nourhène Belaïd; Gihen Dhib; ...
Open Access English
  • Published: 25 Jan 2018
  • Publisher: HAL CCSD
  • Country: France
Abstract
Despite mesenchymal stromal cells (MSCs) are considered as a promising source of cells to modulate immune functions on cells from innate and adaptive immune systems, their clinical use remains restricted (few number, limited in vitro expansion, absence of a full phenotypic characterization, few insights on their in vivo fate). Standardized MSCs derived in vitro from human Induced Pluripotent Stem (huIPS) cells, remediating part of these issues, are considered as well as a valuable tool for therapeutic approaches, but their functions remained to be fully characterized. We generated multipotent MSCs derived from huiPS cells (huiPS-MSCs), and focusing on their immu...
Subjects
free text keywords: [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Immunology, Original Research, induced pluripotent stem cells, mesenchymal stromal cells, human T-cell immunosuppression, regulatory T cells, humanized NSG mouse, tolerance, Immunologic diseases. Allergy, RC581-607, Mesenchymal stem cell, Immune tolerance, Immune system, Cell biology, T cell, medicine.anatomical_structure, medicine, In vivo, Induced pluripotent stem cell, FOXP3, In vitro, Biology
70 references, page 1 of 5

1 Bernardo ME Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell (2013) 13:392–402.10.1016/j.stem.2013.09.006 24094322 [OpenAIRE] [PubMed] [DOI]

2 Horwitz EM Le Blanc K Dominici M Mueller I Slaper-Cortenbach I Marini FC Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy (2005) 7:393–5.10.1080/14653240500319234 16236628 [OpenAIRE] [PubMed] [DOI]

3 Dominici M Le Blanc K Mueller I Slaper-Cortenbach I Marini F Krause D Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8:315–7.10.1080/14653240600855905 16923606 [OpenAIRE] [PubMed] [DOI]

4 Gao F Chiu SM Motan DA Zhang Z Chen L Ji HL Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis (2016) 7:e2062.10.1038/cddis.2015.327 26794657 [OpenAIRE] [PubMed] [DOI]

5 Augello A Tasso R Negrini SM Amateis A Indiveri F Cancedda R Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol (2005) 35:1482–90.10.1002/eji.200425405 15827960 [OpenAIRE] [PubMed] [DOI]

6 Xue Q Luan X-Y Gu Y-Z Wu H-Y Zhang G-B Yu G-H The negative co-signaling molecule B7-H4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev (2010) 19:27–38.10.1089/scd.2009.0076 19788399 [OpenAIRE] [PubMed] [DOI]

7 Selmani Z Naji A Zidi I Favier B Gaiffe E Obert L Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2008) 26:212–22.10.1634/stemcells.2007-0554 17932417 [OpenAIRE] [PubMed] [DOI]

8 Melief SM Schrama E Brugman MH Tiemessen MM Hoogduijn MJ Fibbe WE Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages: MSC induce Tregs through skewing of monocytes. Stem Cells (2013) 31:1980–91.10.1002/stem.1432 23712682 [OpenAIRE] [PubMed] [DOI]

9 Noort WA Kruisselbrink AB in’t Anker PS Kruger M van Bezooijen RL de Paus RA Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp Hematol (2002) 30:870–8.10.1016/S0301-472X(02)00820-2 12160838 [PubMed] [DOI]

10 Maitra B Szekely E Gjini K Laughlin MJ Dennis J Haynesworth SE Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant (2004) 33:597–604.10.1038/sj.bmt.1704400 14716336 [OpenAIRE] [PubMed] [DOI]

11 Polchert D Sobinsky J Douglas G Kidd M Moadsiri A Reina E IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol (2008) 38:1745–55.10.1002/eji.200738129 18493986 [OpenAIRE] [PubMed] [DOI]

12 Horwitz EM Maziarz RT Kebriaei P MSCs in hematopoietic cell transplantation. Biol Blood Marrow Trans (2011) 17:S21–9.10.1 016/j.bbmt.2010.11.026 [OpenAIRE] [DOI]

13 Yin F Battiwalla M Ito S Feng X Chinian F Melenhorst JJ Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses: MSC transplantation biomarkers. Stem Cells (2014) 32:1278–88.10.1002/stem.1638 24452962 [OpenAIRE] [PubMed] [DOI]

14 Le Blanc K Rasmusson I Sundberg B Gotherstrom C Hassan M Uzunel M Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 363:1439–41.10.1016/S0140-6736(04)16104-7 15121408 [OpenAIRE] [PubMed] [DOI]

15 Le Blanc K Frassoni F Ball L Locatelli F Roelofs H Lewis I Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 371:1579–86.10.1016/S0140-6736(08)60690-X 18468541 [OpenAIRE] [PubMed] [DOI]

70 references, page 1 of 5
Abstract
Despite mesenchymal stromal cells (MSCs) are considered as a promising source of cells to modulate immune functions on cells from innate and adaptive immune systems, their clinical use remains restricted (few number, limited in vitro expansion, absence of a full phenotypic characterization, few insights on their in vivo fate). Standardized MSCs derived in vitro from human Induced Pluripotent Stem (huIPS) cells, remediating part of these issues, are considered as well as a valuable tool for therapeutic approaches, but their functions remained to be fully characterized. We generated multipotent MSCs derived from huiPS cells (huiPS-MSCs), and focusing on their immu...
Subjects
free text keywords: [SDV.IMM]Life Sciences [q-bio]/Immunology, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, Immunology, Original Research, induced pluripotent stem cells, mesenchymal stromal cells, human T-cell immunosuppression, regulatory T cells, humanized NSG mouse, tolerance, Immunologic diseases. Allergy, RC581-607, Mesenchymal stem cell, Immune tolerance, Immune system, Cell biology, T cell, medicine.anatomical_structure, medicine, In vivo, Induced pluripotent stem cell, FOXP3, In vitro, Biology
70 references, page 1 of 5

1 Bernardo ME Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell (2013) 13:392–402.10.1016/j.stem.2013.09.006 24094322 [OpenAIRE] [PubMed] [DOI]

2 Horwitz EM Le Blanc K Dominici M Mueller I Slaper-Cortenbach I Marini FC Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy (2005) 7:393–5.10.1080/14653240500319234 16236628 [OpenAIRE] [PubMed] [DOI]

3 Dominici M Le Blanc K Mueller I Slaper-Cortenbach I Marini F Krause D Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy (2006) 8:315–7.10.1080/14653240600855905 16923606 [OpenAIRE] [PubMed] [DOI]

4 Gao F Chiu SM Motan DA Zhang Z Chen L Ji HL Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis (2016) 7:e2062.10.1038/cddis.2015.327 26794657 [OpenAIRE] [PubMed] [DOI]

5 Augello A Tasso R Negrini SM Amateis A Indiveri F Cancedda R Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol (2005) 35:1482–90.10.1002/eji.200425405 15827960 [OpenAIRE] [PubMed] [DOI]

6 Xue Q Luan X-Y Gu Y-Z Wu H-Y Zhang G-B Yu G-H The negative co-signaling molecule B7-H4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev (2010) 19:27–38.10.1089/scd.2009.0076 19788399 [OpenAIRE] [PubMed] [DOI]

7 Selmani Z Naji A Zidi I Favier B Gaiffe E Obert L Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells (2008) 26:212–22.10.1634/stemcells.2007-0554 17932417 [OpenAIRE] [PubMed] [DOI]

8 Melief SM Schrama E Brugman MH Tiemessen MM Hoogduijn MJ Fibbe WE Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages: MSC induce Tregs through skewing of monocytes. Stem Cells (2013) 31:1980–91.10.1002/stem.1432 23712682 [OpenAIRE] [PubMed] [DOI]

9 Noort WA Kruisselbrink AB in’t Anker PS Kruger M van Bezooijen RL de Paus RA Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34+ cells in NOD/SCID mice. Exp Hematol (2002) 30:870–8.10.1016/S0301-472X(02)00820-2 12160838 [PubMed] [DOI]

10 Maitra B Szekely E Gjini K Laughlin MJ Dennis J Haynesworth SE Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant (2004) 33:597–604.10.1038/sj.bmt.1704400 14716336 [OpenAIRE] [PubMed] [DOI]

11 Polchert D Sobinsky J Douglas G Kidd M Moadsiri A Reina E IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol (2008) 38:1745–55.10.1002/eji.200738129 18493986 [OpenAIRE] [PubMed] [DOI]

12 Horwitz EM Maziarz RT Kebriaei P MSCs in hematopoietic cell transplantation. Biol Blood Marrow Trans (2011) 17:S21–9.10.1 016/j.bbmt.2010.11.026 [OpenAIRE] [DOI]

13 Yin F Battiwalla M Ito S Feng X Chinian F Melenhorst JJ Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses: MSC transplantation biomarkers. Stem Cells (2014) 32:1278–88.10.1002/stem.1638 24452962 [OpenAIRE] [PubMed] [DOI]

14 Le Blanc K Rasmusson I Sundberg B Gotherstrom C Hassan M Uzunel M Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 363:1439–41.10.1016/S0140-6736(04)16104-7 15121408 [OpenAIRE] [PubMed] [DOI]

15 Le Blanc K Frassoni F Ball L Locatelli F Roelofs H Lewis I Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet (2008) 371:1579–86.10.1016/S0140-6736(08)60690-X 18468541 [OpenAIRE] [PubMed] [DOI]

70 references, page 1 of 5
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue